I am a
Home I AM A Search Login

Papers of the Week

Papers: 7 May 2022 - 13 May 2022

Human Studies

2022 May 11

J Headache Pain



Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.


Schenk H, Holle D, Nsaka M, Kleinschnitz C, Glas M, Scheffler A
J Headache Pain. 2022 May 11; 23(1):55.
PMID: 35538414.


Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety and tolerability. However, little is known about possible predictors, dose dependence and time course of development of adverse events (AEs) during the treatment under real-world conditions.